Background. Microvascular dysfunction and cardiomyocyte injury are hallmarks of ischemia-reperfusion injury (IRI) after heart transplantation. Platelet-derived growth factors (PDGF) have an ambiguous role in this deleterious cascade. On one hand, PDGF may exert vascular stabilizing and antiapoptotic actions through endothelial-pericyte and endothelial-cardiomyocyte crosstalk in the heart; and on the other hand, PDGF signaling mediates neointimal formation and exacerbates chronic rejection in cardiac allografts. The balance between these potentially harmful and beneficial actions determines the final outcome of cardiac allografts. Methods and Results. We transplanted cardiac allografts from Dark Agouti rat and Balb mouse donors to fully major histocompatibility complex-mismatched Wistar Furth rat or C57 mouse recipients with a clinically relevant 2-hour cold ischemia and 1-hour warm ischemia. Ex vivo intracoronary delivery of adenovirus-mediated gene transfer of recombinant human PDGF-BB upregulated messenger RNA expression of anti-mesenchymal transition and survival factors BMP-7 and Bcl-2 and preserved capillary density in rat cardiac allografts at day 10. In mouse cardiac allografts PDGF receptor-β, but not -α intragraft messenger RNA levels were reduced and capillary protein localization was lost during IRI. The PDGF receptor tyrosine kinase inhibitor imatinib mesylate and a monoclonal antibody against PDGF receptor-α enhanced myocardial damage evidenced by serum cardiac troponin T release in the rat and mouse cardiac allografts 6 hours after reperfusion, respectively. Moreover, imatinib mesylate enhanced rat cardiac allograft vasculopathy, cardiac fibrosis, and late allograft loss at day 56. Conclusions. Our results suggest that PDGF-B signaling may play a role in endothelial and cardiomyocyte recovery from IRI after heart transplantation.
H eart transplantation is the only curative treatment for many end-stage heart diseases. However, shortage of organ donors limits the availability of transplants and leads to the use of donors with extended criteria. 1, 2 Despite careful donor management and current induction and maintenance immunosuppressive therapies, transplant ischemia-reperfusion injury (Tx-IRI), to which the heart is especially vulnerable, remains as one of the major challenges in organ transplantation. 3, 4 Transplant IRI induces microvascular dysfunction that impairs postoperative recovery culminating in increased vascular permeability, perfusion defects, and leukocyte infiltration into the allograft. 5, 6 Furthermore, early microvascular dysfunction predisposes an allograft to ensue vascular remodeling and fibroproliferative processes, leading to untreatable chronic rejection and ultimately allograft failure. [7] [8] [9] [10] Platelet-derived growth factor (PDGF) ligands and their receptors guide physiological mesenchymal cell functions during embryogenesis, angiogenesis, and wound healing. [11] [12] [13] [14] [15] [16] In addition to physiological effects, PDGF has a regulatory role in several pathological conditions, such as arteriosclerosis, rheumatoid and fibroproliferative diseases, and tumor growth. [17] [18] [19] [20] [21] Functional differences between PDGF ligands are mediated by their unique receptor-binding affinity, ability to bind to the extracellular matrix, and activation dependence by proteases. 22, 23 Studies with knockout mice in embryogenesis suggest that PDGF-AA and -CC are the principal ligands responsible for PDGF receptor (PDGFR)-α signaling, and PDGF-BB and PDGF-DD to a lesser extent, for that of PDGFR-β. [24] [25] [26] [27] Divergent from homodimeric PDGF-AA and -BB, PDGF-AB has high affinity to both PDGFR-αα and -αβ, but not -ββ. 28 In cardiac allograft endomyocardial biopsies, PDGF ligands and their receptors are significantly induced during the first postoperative week. 29 Although in rejection PDGF factors remain elevated, interestingly, microvascular levels of PDGFR-β are strongly downregulated. 29, 30 Administration of PDGF-A, -C, and -D provoked pathological coronary intimal and myocardial fibroproliferation in chronic rejection models with minimal Tx-IRI. 30, 31 There is growing evidence supporting the conception that PDGF signaling, especially PDGF-AB and -BB, participate in cardioprotection by, for example, stabilizing leaky myocardial vessels and promoting endothelial and cardiomyocyte survival. [32] [33] [34] [35] [36] [37] [38] Here, we studied the role of PDGF-B during Tx-IRI in rat cardiac allografts.
MATERIALS AND METHODS

Heterotopic Rat Heart Transplantations
Specific pathogen-free fully MHC-mismatched male Dark Agouti (DA, RT1av1) rats served as cardiac allograft donors for male Wistar Furth (RT1u) recipient rats (Scanburg, Göteborg, Sweden). The average weight of the rats was 300 to 350 g. Donor hearts were perfused with heparinized icecold phosphate-buffered saline (PBS) and preserved in +4°C PBS solution for 2 hours after procurement. We used isoflurane as an anesthetic for allograft recipients (2-5%/L O2), and buprenorphine 0.15 mg/kg subcutaneously (Temgesic, 0.3 mg/mL; Schering-Plough, Kenilworth, NJ) for perioperative and postoperative analgesia. We used microsurgical techniques to transplant the cardiac allografts into heterotopic abdominal position of the recipients. Allograft perioperative warm ischemia time needed for surgical procedure was standardized to 1 hour. Allograft recipients in the 10-and 56-day follow-up groups received cyclosporine A (Novartis, Basel, Switzerland) diluted with Intralipid (Fresenius Kabi, Bad Homburg, Germany) 2.0 mg/kg per day subcutaneously the first 7 days and 1.0 mg/kg per day thereafter to prevent severe episodes of acute rejection and to allow the development of an alloimmune response and moderate chronic rejection. To analyze the severity of IRI and the influence of different treatments on it, allografts were removed at 6 hours (N = 9/group) for analysis of myocardial injury and messenger (m)RNA expression. To perform the analysis at the stadium of early immune activation, allografts were collected at 10 days (N = 9/group). To assess the morphological changes of chronic rejection, allografts were collected at 56 days (N = 8/group). Permission for animal experimentation was obtained from the State Provincial Office of Southern Finland. The animals received humane care in compliance with the "Guide for the Care and Use of Laboratory Animals" prepared by the National Academy of Sciences and published by the National Academies Press (ISBN 0-309-15400-6, revised 2011).
Adenovirus Vector Expression by Bioluminescence
Animals treated with a high dose of replication-deficient E1-E3-deleted human serotype 5 adenoviruses under control of the cytomegalovirus (CMV) promoter (Ad5-CMV) exhibit efficient and locally restricted vector transduction. 39 After procurement, cardiac allograft coronary arteries were perfused with Ad5 encoding luciferase under control of the CMV promoter (Ad5-CMV-Luc, 1.0 Â 10 9 plaque-forming unit/mL). The allografts were preserved in +4°C for 2 hours and subjected to perioperative warm ischemia for 1 hour. Noninvasive bioluminescent imaging (IVIS; Xenogen, Alameda, CA) revealed Ad5-CMV-Luc-mediated transgene expression in vivo. The recipients were anesthetized and received luciferase substrate D-Luciferin (bc219; SynChem OHG, Kalles, Germany) 150 mg/kg intravenously 1 minute before bioluminescent imaging. The exposure time was 10 seconds, and the image data was quantified to give measurements of photons/sec/cm 2 /radian (total flux) at the region of the transplanted heart.
Adenovirus Mediated Full-Length Human PDGF-BB Gene Transfer in Rat Cardiac Allografts
Replication-deficient E1-E3-deleted human clinical grade (first generation, serotype 5) adenoviruses were produced under good manufacturing practice conditions in 293T cells, and sample purity was confirmed. 40 After removal, 200 μL of adenoviruses encoding β-galactosidase marker gene (Ad5-CMV-LacZ) (1.0 Â 10 9 pfu/mL; N = 9) or recombinant human full-length (carrying retention motif ) PDGF-BB (Ad5-CMV-PDGF-BB, 1.0 Â 10 9 pfu/mL, N = 9) was perfused transaortically into the coronaries of the donor heart. The allografts were preserved in PBS solution at +4°C for 2 hours and anastomized to the abdominal aorta and inferior vena cava of the recipient, as described. Perioperative allograft warm ischemia was standardized to 1 hour.
PDGF Receptor Tyrosine Kinase Inhibition
To inhibit PDGF receptor activity, protein tyrosine kinase inhibitor imatinib mesylate (Gleevec, Novartis) was diluted with saline to a concentration of 10 mg/mL and administered to the rat cardiac allograft donors 6 hours before procurement and to the rat cardiac allograft recipients at the time of reperfusion and daily thereafter at a dose of 10 mg/kg intraperitoneally. Control cardiac allograft recipients received intraperitoneal saline vehicle solution.
Effect of PDGFR-a and -b mAb on Mouse Cardiac Allograft IRI Inbred male BALB/c (B/c, H-2d) and C57BL/6J (B6, H-2b) mice (Harlan, Horst, The Netherlands), 2 to 3 months of age were used. Allograft donors were treated with rat IgG (Sigma-Aldrich, St. Louise, MO) 800 μg intraperitoneally or rat antimouse PDGFR-α (1E10; Eli Lilly and Company, New York, NY) or -β (2C5; Eli Lilly and Company) neutralizing antibody 800 μg intraperitoneally 1 day before cardiac procurement. The intraperitoneal injection of monoclonal antibody 24 hours before cardiac procurement to allow the antibodies to access the circulation after the intraperitoneal injection and have enough time to perfuse the cardiac tissue and saturate the receptors. 41 We used the same microsurgical techniques for mouse heterotopic cardiac transplantation as in rat model. Donor hearts were perfused with heparinized ice-cold PBS and preserved in +4°C PBS solution for 2 hours after procurement. Allograft perioperative warm ischemia time needed for surgical procedure was standardized to 1 hour. The allografts were collected 6 hours after reperfusion. The use of heterotopic mouse heart transplantations was necessary because the specific rat antimouse PDGFR-α and -β neutralizing antibodies are not available in antirat isoform. The coding region of the human PDGF-B cDNAwas cloned into the psub-CMV-WPRE AAV2 expression vector. The rAAVs were produced with the 2-plasmid transfection method in 293T cells and purified by iodixanol-gradient ultracentrifugation and heparin-sepharose high-performance liquid chromatography. The expression of the recombinant proteins was verified by metabolically labeled 293T cells transduced with the rAAVs. The expression of the proteins was analyzed by coprecipitation with the respective receptor-Ig molecules, and the resultant protein complexes were separated in sodium dodecyl sulfate polyacrylamide gel electrophoresi. Rat gastrocnemius muscle was perfused with 200 μL of adenoassociated virus serotype 2 (1.4 Â 10 11 viral particles) encoding recombinant human full-length PDGF-B or human serum albumin, under control of the CMV promoter (AAV2-CMV-PDGF-B and AAV2-CMV-human serum albumin). Tissue samples were collected at 30 days for analysis of pericyte investment.
Measurement of Cardiac Troponin T
The rat serum levels of cardiac troponin T (cTnT) were analyzed with the fifth generation troponin T test (Troponin T STAT; Roche Diagnostics, Basel, Switzerland). The cTnT was measured by electrochemiluminescence immunoassay on the Elecsys 2010 immunoassay analyser (Roche Diagnostics).
In Situ Apoptosis Detection
The analysis of cardiac allograft cardiomyocyte apoptosis was based on terminal deoxynucleotidyl-transferase-mediated 2′-deoxyuridine 5′-triphosphate nick end-labeling assay (TUNEL). Paraformaldehyde-fixed 4-μm-thick paraffin sections were stained with in situ apoptosis detection kit (TA5353, CardioTACS; R&D Systems, Minneapolis, MN). The TUNEL-positive apoptotic cardiomyocyte nuclei were counted from 4 random fields of each quadrant of the cardiac cross section with 40Â magnification, and the results are given as the mean number of positive cells per 1 mm. 2 
Immunohistochemistry and Immunofluorescence Stainings
Cryostat sections were stained using the peroxidase ABC method (Vectastain Elite ABC Kit; Vector Laboratories, Inc., Burlingame, CA), and the reaction was revealed by 3-amino-9-ethylcarbazole (Vector Laboratories). Counterstaining was performed using Mayer hemalum. Immunofluorescent stainings were performed using Alexa 568 red and Alexa 488 green (Promega, Madison, WI) secondary antibodies.
Antibodies and dilutions used according to specific objectives were:
(1) to quantify the inflammatory cells in the allografts: anti-rat CD4 (5 μg/mL, 22021D), antimouse CD4 (5 μg/mL, 553043), antirat CD8 (5 μg/ml, 22071D), anti-mouse CD8 (5 μg/mL, 553027), CD11b for mouse macrophages (5 μg/mL, 553308), ED1 for rat macrophages (5 μg/mL, 22451D; BD Pharmingen, Franklin Lakes, NJ); CD11c for mouse dendritic cells (10 μg/mL, ab33483), myeloperoxidase to detect rat and mouse neutrophil granulocytes (20 μg/mL, ab9535); (2) to analyze and quantify the structural characteristics of the cardiac tissue: tropomyosin (7 μg/mL, ab7785), NG2 for neural/glial antigen 2 (15 μg/mL, ab50009; Abcam, Cambridge, United Kingdom); RECA-1 for rat endothelial cell antigen (50 μg/mL, MCA97; AbD Serotec, Dusseldorf, Germany); α-SMA for anti-α smooth muscle actin antibody (1:5000, A2547; Sigma-Aldrich); (3) to visualize the PDGF-B and its receptors: PDGFR-α (2 μg/mL, sc-338), PDGFR-β (2 μg/mL, sc-339), PDGF-B (2 μg/mL, sc-7878; Santa Cruz Biotechnology, Santa Cruz, CA); (4) to localize β-galactosidase control gene (Ad.LacZ):
β-galactosidase (1 μg/mL, MON5013, Sanbio V.B., AM Uden, The Netherlands).
Inflammatory cells, RECA1 + capillaries and α-SMA arteries were determined by counting positive cells and vessels from 4 random fields of each quadrant of the cardiac crosssection with magnification 40Â, and the results are given as the mean number per 1 mm 2 .
Measurement of Syndecan-1
For syndecan-1 measurements in serum samples, we used solid-phase ELISA kits (SEB966Ra, design by Cloud-Clone Corp. Houston, TX, assembled by Uscn Life Science Inc., Cologne, Germany). The plates were analyzed using the BioRad microplate reader (Bio-Rad Laboratories, Inc., Hercules, CA) at a wavelength of 450 nm. Frozen (−20°C) serum samples were thawed and shortly spinned. One hundred microliters of standard, blanco, and diluted samples (1:8 in 0.01 M PBS) was used per well. Standard curves were constructed by plotting the concentration and mean absorbance at 450 nm. To calculate the concentration, the standards were fitted with a second-order polynomial equation.
RNA Isolation and Reverse Transcription
Total RNA was extracted from myocardial samples using RNeasy Mini Kit (Qiagen, Hilden, Germany). Reverse transcription of mRNA was carried out from 100 ng total RNA using High-RNA-to-cDNA kit (Applied Biosystems Inc., Carlsbad, CA) in a total volume of 20 μL. After completed reverse transcription, 40 μL of polymerase chain reaction (PCR)-water was added to each cDNA sample. Three microliters of each sample (corresponding to 5 ng total RNA) was used in each subsequent PCR reaction.
Quantitative Real-Time PCR
Quantitative real-time PCR reactions were carried out on a RotorGene-6000 (Corbett Research, Hilden, Germany) using 2Â DyNAmo Flash SYBR Green Master mix (Finnzymes, Espoo, Finland). Measurement of the PCR product was performed at the end of each extension period. Amplification specificity was checked using melting curve analysis. The number of mRNA copies of each gene of interest was calculated from a corresponding standard curve using the RotorGene software. The results are given in relation to 18S rRNA molecule numbers.
Histology
Cardiac fibrosis was determined in a blinded review by 2 observers from paraformaldehyde fixed paraffin sections stained with Masson trichrome and scored semiquantitatively (0 to 3) as follows: 0, no fibrosis; 1, mild; 2, moderate; and 3, severe myocardial fibrosis. Myocardial area and arterial occlusion were determined from allograft midline cross sections using computer-assisted image processing (Zeiss Axiovision 4.4; Carl Zeiss International, Oberkochen, Germany). To measure myocardial area and cardiac allograft vasculopathy, the sections were stained with hematoxylin-eosin and ResorcinFuchsin for internal elastic lamina. The area between the internal elastic lamina and the vessel lumen represents the neointimal area. The percentage of arterial occlusion was determined as the ratio of the neointimal area to the internal elastic lamina area. Additionally, arterial occlusion grade was determined using the Billingham criteria 42 : grade 0, normal artery with intact internal elastic lamina; grade 1, less than 10% occlusion of lumen by arterial intimal thickening and proliferation, disruption of internal elastic lamina, some foam or vacuolated endothelial cells may be present; grade 2; less than 50% occlusion of the lumen; grade 3, greater than 50% but less than 100% occlusion of lumen; and grade 4, 100% vessel occlusion of lumen.
Allograft Function
Allograft function was estimated by daily abdominal palpation and graded according to heart beat from 0 to 4: 0 minimal or no contractility (heart beat <30 bpm); 1, poor; 2, moderate; 3, impaired; 4, normal. The allografts were removed when the grade fell to 0.
Statistics
All data are mean ± SEM and analyzed by SPSS 15.0 (SPSS Inc
RESULTS
Adenovirus-Mediated Gene Transfer of PDGF-BB Results in Efficient Transgene Expression in Rat Cardiac Allografts
We perfused the coronaries of rat cardiac allografts ex vivo with Ad.Luc immediately after the procurement, subjected the allografts for 2-hour cold ischemia and transplanted the allografts with 1-hour warm ischemia. For the first 5 days, and 10, 14, 21, 28, and 180 days after reperfusion, we imaged luciferase activity. In vivo bioluminescent imaging localized the luciferase activity to the abdominal region of the recipient, where the transfected allograft was transplanted. FIGURE 1. Intracoronary Ad.hPDGF-BB-mediated gene transfer in rat cardiac allografts. Replication-deficient E1-E3-deprived human serotype 5 adenoviruses encoding transgene under control of the CMV promoter were injected into the cardiac allograft coronary arteries (1.0 Â 10 11 viral particles) after the procurement. Cardiac allografts were preserved for 2 hours in +4°C and subjected to 1-hour warm ischemia during the transplantation. Allograft recipients were treated subcutaneously with cyclosporine A 2 mg/kg per day for the first 7 days and thereafter 1 mg/kg per day. A, Bioluminescent optical imaging of rat recipients of luciferase transfected (Ad.Luc) cardiac allografts was performed in vivo until day 180. 10 second exposure started 1 minute after intravenous injection of D-luciferin (150 mg/kg of body weight). The signal intensity in the region of interest (ROI) is expressed as photons per second (sec) per centimeter squared (cm 2 ). B, Luciferase transgene expression in cardiac allograft (arrow), and in recipient liver (arrowhead). C, To localize transgene expression in cardiac allografts, donor hearts were perfused intracoronarily with adenoviruses that express β-galactosidase control gene (Ad.LacZ). In Ad.LacZ-perfused allografts, immunoreactivity of the control gene localized to tropomyosin + cardiomyocytes 10 days after reperfusion. D, Uniformly in Ad.hPDGF-BB perfused allografts, immunoreactivity of PDGF-B (arrow) localized to cardiomyocytes 10 days after reperfusion. Vascular PDGF-B immunoreactivity (arrow) at 10 day in Ad.LacZ perfused allograft (inset). E, Quantitative PCR analysis of human PDGF-B mRNA expression 10 days after reperfusion. Red dashed line (A) represent background bioluminescence in rat recipients without luciferase transfected (no virus) cardiac allografts. n = 9 / group. For representative images of immunoreactivity of β-galactosidase control gene (original magnification, 63Â) and PDGF-B (40Â), scale bars = 50 μm.
Luciferase activity peaked at day 5 ( Figure 1A and B) and was observed in vivo until day 180 ( Figure 1A) . Because of the hepatotropic nature of adenovirus, and the highly fenestrated and permeable hepatic vasculature, a weak luciferase signal was also detectable in the recipient liver ( Figure 1B) . Because the doses used in our study may comprise of some immune reactions and increase in monocyte-macrophages, graft-infiltrating inflammatory cells were analyzed. No differences were observed between Ad.Luc perfused and control (no virus) allografts at 180 days ( Figure S1 , SDC, http://links.lww.com/TP/B189). Next, we perfused the cardiac allografts with Ad.LacZ to pinpoint the precise location of the allograft transgene expression by immunofluorescence staining of cross-sections. At 10 days, β-galactosidase control gene expression was localized to the tropomyosin + cardiomyocytes of cardiac allografts ( Figure 1C) . Similarly, Ad.hPDGF-BB perfusion (adenotransduction forms intracellularly BB dimer) resulted in PDGF-B immunoreactivity in the cardiomyocytes of cardiac allografts at 10 days ( Figure 1D ). Finally, quantitative PCR revealed that human PDGF-B mRNA expression was exclusive to Ad.hPDGF-BB perfused allografts at 10 days when compared to Ad.LacZ perfused allografts ( Figure 1E ).
Adenovirus-Mediated PDGF-BB Gene Transfer Maintains Cardiac Allograft Microvascular Density
The coronary arteries of rat cardiac allografts were perfused ex vivo with either Ad.LacZ control gene or Ad. hPDGF-BB and removed for analysis 10 days after reperfusion. To evaluate endothelial injury of cardiac allografts, the serum release of syndecan-1 in the recipient, as an indicator of endothelial glycocalyx shedding, was analyzed by ELISA. Serum syndecan-1 levels were 20-fold higher in the recipients of Ad.LacZ-perfused allografts compared to serum levels of native DA rats (Figure 2A ). In the recipients of Ad. hPDGF-BB cardiac allografts serum syndecan-1 levels were significantly reduced when compared to the recipients of Ad.LacZ allografts (P < 0.05; Figure 2A ). Immunohistochemistry of cardiac cross-sections revealed that cardiac allografts perfused with Ad.LacZ control gene had diminished density of RECA1 + myocardial capillaries compared to native DA rat hearts. Ad.hPDGF-BB gene transfer preserved RECA1 + myocardial capillary density (P < 0.01; Figure 2B ), but did not affect the density of α-SMA + vessels at 10 days ( Figure 2C ). Quantitative real time quantitative real time reverse transcription polymerase chain reaction revealed that hPDGF-BB gene transfer induced the mRNA expression of BMP-7, an inhibitor of the endothelial-mesenchymal transition (EndMT) (P < 0.05; Figure 2D ), 43 and antiapoptotic Bcl-2 (P < 0.001; Figure 2D ). However, the mRNA expression of important anti-inflammatory heme oxygenase 1 (HO-1), and endothelial nitric oxide synthase, was not induced by hPDGF-BB gene transfer. The numbers of allograft infiltrating myeloperoxidase + neutrophils, ED1 + macrophages, and CD4 + and CD8 + T cells were similar between Ad.LacZand Ad.hPDGF-BB-perfused allografts ( Figure 2E ).
We stained cardiac allograft cross-sections with pericyte marker NG2, PDGFR-β, and α-SMA to dissect the role of pericyte recruitment in cardiac allografts overexpressing PDGF-BB. At 10 days, Ad.hPDGF-BB gene transfer induced local pericyte accumulation around transduced cardiac allograft cardiomyocytes ( Figure S2A , SDC, http://links.lww.com/TP/B189). Similar local results were achieved at 30 days after the injection of AAV2-hPDGF-B into the rat gastrocnemius muscle ( Figure S2B , SDC, http://links.lww.com/TP/B189). Capillary pericyte coverage in Ad.LacZ and Ad.hPDGF-BB perfused cardiac allografts remained however comparable at 10 days ( Figure S3 , SDC, http://links.lww.com/TP/B189).
PDGF Receptor Tyrosine Inhibitor Enhances IRI in Rat Cardiac Allografts Subjected to Ischemic Preservation
Next, we used PDGF receptor tyrosine kinase inhibitor imatinib mesylate to investigate the effects of PDGF receptor inhibition on Tx-IRI and long-term survival of rat cardiac allografts. Treatment with imatinib mesylate increased the levels of serum syndecan-1 and cTnT, indicators of endothelial and cardiomyocyte injury, in rat cardiac allograft recipients 6 hours after reperfusion, respectively, when compared to the recipients treated with vehicle (P < 0.05 for both; Figure 3A and B). However, PDGF receptor tyrosine inhibitor had no effect on the number on TUNEL + cells in rat cardiac allograft recipients 6 hours after reperfusion, when compared to the recipients treated with vehicle ( Figure 3C ).
PDGF Receptor Tyrosine Inhibitor Enhances Chronic Rejection in Rat Cardiac Allografts Subjected to Ischemic Preservation
In the chronic rejection model, treatment with imatinib mesylate increased the number of allograft infiltrating myeloperoxidase + neutrophils and ED1 + macrophages (P < 0.05; Figure 4A ), but had no effect on the number of infiltrating FIGURE 3. Inhibition of PDGF receptor activity induces endothelial glycocalyx shedding and cardiomyocyte injury in rat cardiac allografts. Specific PDGFR inhibition by protein tyrosine kinase inhibitor imatinib mesylate was given intraperitoneally to cardiac allograft donors 6 hours before procurement. The effect of imatinib mesylate on recipient serum (A) syndecan-1 protein and (B) cTnT levels 6 hours after allograft reperfusion. C, Cardiac allografts were analyzed for TUNEL + apoptotic cells. Red dashed lines represent (A) syndecan-1 protein levels and (B) cTnT levels in native recipient WF rats and (C) TUNEL + apoptotic cells in native donor DA hearts. n = 9/group. For representative images of TUNEL staining (original magnification, 100Â), scale bar = 50 μm. *P < 0.05.
CD4
+ and CD8 + T cells ( Figure 4A ). Further, treatment with imatinib mesylate increased the proapoptotic Bax/Bcl-2 mRNA ratio (P < 0.05; Figure 4B ), without affecting the mRNA expression of endothelial nitric oxide synthase, heme oxygenase 1, IL-1, IL-2, TNF-α, IFN-γ, or MCP-1 ( Figure 4B ). Importantly, treatment with imatinib mesylate decreased the cardiac allograft survival rate to 57%, whereas all control allografts in vehicletreated recipients survived throughout the experimental period (P < 0.05; Figure 5B ). Treatment with imatinib mesylate enhanced hypertrophy, as evidenced by the allograft crosssectional area (P < 0.001; Figure 5C ), cardiac fibrosis (P < 0.05; Figure 5D ), and allograft vasculopathy (P < 0.05; Figure 5E ), when compared to allografts in vehicle-treated recipients.
Inhibition of PDGF Receptor-a Enhances IRI in Mouse Cardiac Allografts Subjected to Ischemic Preservation
We aimed to dissect the specific roles of PDGF receptors -α and -β in cardiac allograft Tx-IRI. Major MHC-mismatched mouse cardiac allografts were harvested 6 hours after reperfusion for analysis of PDGF receptor mRNA expression by quantitative PCR and protein localization by immunohistochemistry. Intragraft mRNA levels of PDGFR-α were induced, whereas PDGFR-β reduced when compared to native mouse hearts ( Figure S4A , SDC, http://links.lww.com/TP/B189). At protein level, allograft PDGFR-α induction localized most strongly in infiltrating inflammatory cells, whereas microvascular PDGFR-β immunoreactivity was nearly lost ( Figure S4B , SDC, http://links.lww.com/TP/B189). Finally, major MHC-mismatched mouse allograft donors were treated with specific PDGFR-α and -β mAbs. Blocking PDGFR-α, but not -β signaling resulted in increased myocardial damage six hours after reperfusion as evidenced by serum cTnT when compared to IgG controls (P < 0.05, Figure 6 ). No changes were observed between the study groups in the levels of allograft infiltrating CD4 + T cells, myeloperoxidase + neutrophils, CD11b
+ macrophages, and CD11c + dendritic cells ( Figure S5A -D, SDC, http://links.lww.com/TP/B189).
DISCUSSION
Ischemia-reperfusion injury is a major risk factor for microvascular dysfunction and myocardial damage after heart transplantation. Current immunosuppressive therapies target recipient T cell-mediated adaptive immunity. However, donor modalities that target Tx-IRI could restrain allograft immunogenicity and the subsequent adaptive immune responses.
We have previously shown that blocking PDGF receptor activity with tyrosine kinase inhibitors reduces alloimmune activation and allograft vasculopathy in rat and rabbit cardiac allografts when these allografts were not subjected to cold ischemic preservation. [44] [45] [46] According to the Registry of International Society of Heart and Lung Transplantation, the ischemia time for heart transplantation is 3.3 hours in the current era. 47 Furthermore, there is evidence to suggest that ischemia time enhances IRI and the development of chronic rejection. 48 Mechanistically, prolonged ischemia is linked in enhanced innate and alloimmune responses through the activation of toll-like receptors in the antigen presenting cells. 49 However, experimental studies with cardiac allografts usually disregard clinically relevant ischemia times and thus fail to equal clinical Tx-IRI.
Intracoronarily administered adenoviral gene transfer is feasible for rapid and diffuse distribution of the target molecule exclusively within the transplant to eliminate systemic effects. Here, we show that clinically applicable ex vivo human PDGF-B gene transfer into the coronary arteries of cardiac allografts subjected to clinically relevant cold ischemia maintained cardiac allograft capillary density, whereas inhibition of PDGF receptor signaling in these allografts enhanced myocardial injury, development of cardiac fibrosis, and allograft vasculopathy. In the current study, introduction of innate injury to the cardiac allograft by means of a prolonged 2-hour cold ischemia time revealed cardioprotective characteristics of angiogenic growth factors. During hypoxia and metabolic compromise, PDGF-AB and -BB ligands play a pivotal role in microvascular and cardiomyocyte survivals, endothelial repair, vascular stability and inhibition of inflammation, and cardiomyocyte contractile function. 33, 35, 38, [50] [51] [52] Moreover, PDGF-BB pretreatment protects neurons from toxicity-induced and lung fibroblasts from starvation-induced apoptosis. 53, 54 Nevertheless, prolonged upregulation of PDGF-B may contribute to fibroproliferation and neointimal formation by recruiting mesenchymal cells and enhancing their proliferation and survival. 55, 56 Here, we showed that adenoviral human PDGF-BB gene transfer reduced endothelial glycocalyx shedding, induced allograft mRNA expression of anti-EndMT and antiapoptotic factors, and maintained myocardial capillary density 10 days after reperfusion. This is in accordance with previous observations of the regenerative qualities of both syndecan-1 and PDGF-B expression in tissues. [57] [58] [59] Furthermore, as described previously, [35] [36] [37] PDGF-BB is cardioprotective in acute myocardial infarction. On the other hand, loss of endothelial glycocalyx and reduction in growth factor levels may (i) enhance EC apoptosis, (ii) reduce endothelial regeneration capabilities, and (iii) induce EndMT. 34, [60] [61] [62] Imatinib mesylate is a potent PDGF receptor inhibitor. 63 Administration of imatinib mesylate reversed advanced pulmonary vascular neointima formation and reduced carotid artery stenosis by inducing vascular smooth muscle cell apoptosis. 21, 64 Furthermore, blockade of PDGF receptor signaling abrogated PDGF-B-dependent survival and induced the activation of procaspase-3 (a precursor of caspase3, which is activated in the apoptotic cell both by extrinsic [death ligand] and intrinsic [mitochondrial] pathways) 65 and apoptosis of microvascular endothelial cells. 34 Moreover, PDGF receptor inhibition is associated with heart failure. 66, 67 Another report has shown that activation of survival pathways in hypoxia is PDGF-B/PDGFR-β-dependent. 68 This is in concordance with our findings that tyrosine kinase inhibitor imatinib mesylate induced cardiac allograft cardiomyocyte injury after IRI and the late development of chronic rejection. Interestingly however, our results showed that PDGFR-α, but not -β inhibition specifically induced myocardial injury after IRI in mouse cardiac transplants. As we show here, loss of microvascular PDGFR-β immunoreactivity in mouse cardiac Tx-IRI is similar to that of rejecting rat cardiac allografts, 30 the role of PDGFR-β stabilization instead of blocking it is warranted when studying cardiac allograft Tx-IRI and rejection.
Interestingly, the upregulation of PDGF-BB had a protective effect on microvascular survival, but blocking its receptor had no harmful effect in our experiments. Vascular expression of PDGFR-β is downregulated in IRI and in acute allograft rejection in mouse (as demonstrated in this study) and in rat. 30 This might directly lead to the harmful loss of cardio-and vasculoprotective effect PDGF-BB signaling, explaining why upregulation of PDGF-BB has a protective effect on microvascular survival. On the other hand, blocking the already downregulated PDGFR-β cannot induce any additional damage. Thus, maintaining vascular PDGFR-β signaling during IRI or acute allograft rejection appears to be the beneficial therapeutic strategy.
Viral gene therapy offers a sophisticated method for efficient, locally restricted, and safe protein distribution, and has been used to improve healing in multiple tissues. 69, 70 Adenoviruses have relatively rapid and high in vivo vector transduction efficacy and transplants are easily transfected during graft removal and preservation. In summary, we demonstrate that PDGF-BB enhances microvascular survival in cardiac allografts. Perioperative PDGF-BB gene therapy facilitates FIGURE 6 . Inhibition of PDGF receptor -α, but not -β induces cardiomyocyte injury in mouse cardiac allografts. Mouse cardiac allograft donors were treated with IgG control or monoclonal PDGFR-α or PDGFR-β antibody intraperitoneally 24 hours before procurement. The effect of specific PDGFR-α or -β inhibition was investigated on (A) recipient serum cTnT levels 6 hours after allograft reperfusion. B, Cardiac allografts were analyzed for TUNEL + apoptotic cells. Red dashed lines represent (A) cTnT levels in native recipient WF rats and (B) TUNEL + apoptotic cells in native donor DA hearts. n=6-7 / group. For representative images of TUNEL staining (original magnification, 40Â), scale bar = 50 μm. *P < 0.05.
